Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when ProxsysRx launched its 340B Support Services division, we’ve managed the 340B programs of 21 health systems. Altogether, we’ve generated more than $500 million in 340B Savings and Revenue for those health systems — $98M in the first 10 months … Read More
In late 2022, ProxsysRx’s team initiated 340B Program-Management support for a 198-bed, full-service, community and regional non-profit medical center located in the Northeast. After weeks of laying all the necessary groundwork to manage its 340B program, we began actively submitting eligible prescriptions this past January. By the end of Q1, the hospital’s 2023 340B savings … Read More
Why 340B vendors charging Percentage Of Revenue is wrong. From time to time, 340B hospitals are required to purchase non-eligible prescriptions at the Wholesale Acquisition Cost. When that happens, the costs of those medications often exceed reimbursement. Most 340B hospitals already operate on a loss-basis. Which is why, we believe, it’s so wrong for 340B … Read More
To date, we’ve published a dozen posts either detailing, or mentioning-in-passing, the clinical and financial benefits a well-run Meds To Beds program offers hospitals and the patients they serve. Which is why we thought it was time to report some of the personal benefits our program delivers — with a handful of stories we’ve heard … Read More
Since the advent of 340B ESP in 2020, drug manufacturers have imposed a raft of unlawful restrictions on 340B program savings. Nowhere have those restrictions been more punitive than with specialty pharmacy medications; drugs which typically represent the most expensive (and profitable) in manufacturers’ product lines. 340B restrictions from the drug manufacturers’ perspective That said, … Read More
Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when ProxsysRx launched its 340B Support Services division, we’ve managed the 340B programs of 18 health systems. We’ve generated more than $500 million in 340B Savings and Revenue. And yet, we’ve never served (or seen) a 340B health system with … Read More
The 340B-program landscape has changed dramatically. For the 340B program’s first 28 years after its 1992 inception, the basic list of Best Practices for eligible entities (the 340B basics, if you will) remained largely unchanged — aside from the dramatically-increased importance of using specialized software. But since the June, 2020 introduction of 340B ESP — … Read More
340B ESP and drug manufacturer restrictions are only part of the reason As we noted in a previous post, for 340B-eligible hospitals dealing with increasingly squeezed bottom lines, an in-house specialty pharmacy offers enormous savings and revenue potential. Some covered entities generate as much as 600% in specialty pharmacy revenue from 340B drugs as they … Read More
A ProxsysRx Team Member Speaks Out. I joined ProxsysRx in early 2021, and I’ve been devoted to 340B program management full-time since early 2022. I’m no stranger to heavily regulated programs. Nearly my whole professional career has been in some aspect of public health — preclinical, clinical and now post-clinical. I’m currently fully devoted to … Read More
In late 2022, ProxsysRx’s team initiated 340B Program-Management support for a regional non-profit medical center located in the Northeast. We began actively submitting eligible prescriptions in January, 2023. By the end of Q1, the hospital’s 2023 340B savings & revenue had surpassed its total for all of 2022. Below is a brief review of how … Read More
